Liposome medicine and application thereof in relieving asthma
By encapsulating rosmarinic acid and tanshinone IIA in the phospholipid bilayer membrane, the side effects of inhaled glucocorticoid drugs were solved, significantly improved the therapeutic effect of asthma, and provided new anti-asthma drug development direction.
Patent Information
- Application Number
- CN202411104233.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-13
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing inhaled glucocorticoid drugs for the treatment of asthma have serious side effects in high doses or long-term use, resulting in the urgent need for finding new, safe and effective drugs.
Liposomal drugs are used to encapsulate rosemary acid and tanshinone IIA in a phospholipid bilayer membrane, and a specific structure of liposomal drugs are formed through specific weight ratios and preparation methods to relieve asthma.
It significantly enhances the therapeutic effect on asthma, provides a new direction for the development of anti-asthma drugs, reduces the total number of cells and Th2 cytokine concentration in bronchial alveolar lavage fluid, and improves the safety and effectiveness of the drug.
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biomedicine, and specifically relates to a liposome drug and its application in relieving asthma. Background Art
[0002] Asthma is a serious health problem that exists all over the world, seriously affecting people's daily lives and sometimes even causing fatal injuries. Allergic asthma is a heterogeneous airway conduction disorder, including chronic airway inflammation, decreased airway function and airway tissue remodeling. Its main pathological features are mucus hypersecretion, airway obstruction, airway inflammation and airway hyperresponsiveness. Asthma is believed to be caused by the interaction of genetic factors and environmental influences, such as the infection dose and infection time of allergens and contact infection. At present, inhaled corticosteroids play a major role in the prevention and treatment of asthma. Although inhaled corticosteroids are generally effective, their high doses or long-term use can lead to serious side effects, such as growth retardation, adrenal suppression, fractures, liver damage, cancer and stroke risks, which makes them face a long-term dilemma in clinical use. Therefore, finding new, safe and effective drugs to prevent or treat asthma has become an urgent need.
[0003] Rosmarinic acid, English name: rosmarinci acid, is a water-soluble natural phenolic acid compound isolated from the Labiatae plant rosemary. The chemical name is R (t) 2-[[3-(3, 4. dihydroxyphenyl) -1-oxo-2-propenyl] oxy] -3, 4-dihydroxyphenylpropionic acid, which is formed by the condensation of one molecule of caffeic acid and one molecule of 3, 4. dihydroxyphenyl lactic acid. Rosmarinic acid is widely distributed in plants, mainly distributed in a variety of plants such as the Labiatae, Boraginaceae, Umbelliferae, Cucurbitaceae and Apiaceae. Rosmarinic acid is a herb used for both medicinal and edible purposes, which can be used for viewing and extracting fragrance, and can also be used as a food seasoning. A large number of studies have shown that rosmarinic acid has multiple pharmacological effects such as antioxidant, antibacterial, antiviral, and antidepressant. At present, rosmarinic acid has shown its important application value in the fields of pharmaceuticals, food, and cosmetics.
[0004] Therefore, Chinese invention patent CN105997974A discloses the use of rosmarinic acid in the preparation of a drug for treating asthma. However, the efficacy of directly using rosmarinic acid to treat asthma still needs further improvement. The present invention is an improvement proposed to address this technical problem. Summary of the invention
[0005] In order to solve the defects of the prior art, the present invention proposes a liposome drug and its application in relieving asthma. Specifically, in order to achieve the purpose of the present invention, the present invention intends to adopt the following technical solutions:
[0006] One aspect of the present invention relates to a liposome drug, wherein the liposome is a liposome formed by a phospholipid bilayer membrane, wherein rosmarinic acid is encapsulated inside the liposome, and tanshinone IIA is encapsulated in the phospholipid bilayer membrane of the liposome.
[0007] In a preferred embodiment of the present invention, the liposomes are formed from DPPC, DSPG and cholesterol.
[0008] In a preferred embodiment of the present invention, the weight ratio of DPPC, DSPG and cholesterol is 40-60:5-8:12-15.
[0009] In a preferred embodiment of the present invention, the weight ratio of rosmarinic acid to tanshinone IIA is 60:15-120; preferably 60:18.
[0010] In a preferred embodiment of the present invention, the liposome medicine does not contain other active ingredients.
[0011] Another aspect of the present invention also relates to a method for preparing the above liposome drug, which comprises the following steps:
[0012] (1) Preparation of rosmarinic acid solution: adding rosmarinic acid to purified water and dissolving by ultrasonication;
[0013] (2) Mixing the rosmarinic acid solution with the lipid solution: Mix tanshinone IIA, DPPC, DSPG and cholesterol, then add chloroform and methanol to mix easily, and gently shake to dissolve tanshinone IIA, DPPC and DSPG; Use a rotary evaporator to remove the solvent until a thin film of dry lipids is deposited on the wall of the container; Add the rosmarinic acid solution to the round-bottom flask containing the thin layer of dry lipids and sonicate at a temperature of 60-70 degrees Celsius;
[0014] (3) Extrusion: The preparation was extruded at 60-70 degrees Celsius using a heated stainless steel extruder equipped with a polycarbonate membrane. The extrusion process was repeated 9-11 times to obtain liposomes of 80-200 nm. After extrusion, NaOH was added to the liposome solution to adjust the pH to 6.5-7.0 to obtain liposomal drugs.
[0015] Another aspect of the present invention also relates to the use of the above liposome drug in the preparation of drugs for relieving asthma.
[0016] Beneficial Effects
[0017] The present invention creatively prepares rosmarinic acid and tanshinone IIA into a liposome drug with a specific structure. Through the synergistic effect of rosmarinic acid and tanshinone IIA, the drug effectively enhances the therapeutic effect on ovalbumin (OVA)-induced asthma in mice, providing a new direction for the research and development of anti-asthma drugs. DETAILED DESCRIPTION
[0018] In order to further understand the present invention, the technical solutions in the embodiments of the present invention will be clearly and completely described below in combination with the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.
[0019] Unless otherwise specified, the reagents involved in the embodiments of the present invention are all commercially available products and can be purchased through commercial channels.
[0020] Example 1
[0021] (1) Preparation of rosmarinic acid solution: rosmarinic acid (300 mg) was added to a beaker containing 100 ml of purified water and then dissolved by ultrasonication for 10 minutes.
[0022] (2) Mixing rosmarinic acid solution with lipid solution: Tanshinone IIA (18 mg), DPPC (40 mg), DSPG (5 mg) and cholesterol (12 mg) were mixed in a 50 ml round-bottom flask, and then 18 ml of chloroform and 2 ml of methanol were added and gently shaken to dissolve Tanshinone IIA, DPPC and DSPG. The solvent was removed using a rotary evaporator at 65 ° C until a thin film of dry lipids was deposited on the wall of the flask. Finally, 20 ml of the prepared rosmarinic acid solution was added to the round-bottom flask containing the thin layer of dry lipids and sonicated at 65 ° C for about 30 minutes.
[0023] (3) Extrusion: The formulation was extruded at 65°C using a heated stainless steel extruder equipped with a polycarbonate membrane to reduce the size of the liposomes and improve uniformity. The extrusion process was repeated 9-11 times to obtain liposomes of 80-200 nm. After extrusion, NaOH was added to the liposome solution to adjust the pH to 6.5-7.0 to obtain the liposomal drug.
[0024] Example 2
[0025] The same as Example 1, except that the content of Tanshinone IIA is 28 mg.
[0026] Example 3
[0027] The same as Example 1, except that the amount of rosmarinic acid is 500 mg.
[0028] Comparative Example 1
[0029] The same as Example 1, except that Tanshinone IIA was not added.
[0030] Comparative Example 2
[0031] The same as Example 1, except that rosmarinic acid and tanshinone IIA were dispersed together in deionized water, and then the rosmarinic acid and tanshinone IIA dispersion was added to the round-bottom flask containing the dried lipid thin layer.
[0032] Example 4
[0033] 1. Establishment of mouse asthma model
[0034] 64 female BABL / c mice weighing 18-20g were randomly selected and divided into a blank control group, a model group, a rosmarinic acid group, an embodiment 1-3 group and a comparative example 1-2 group, with 8 mice in each group; on the 0th day, the 7th day and the 14th day, the mice in the model group, the rosmarinic acid group, the embodiment 1-3 group and the comparative example 1-2 group were respectively injected with OVA (ovalbumin) sensitization solution in the peritoneal cavity, the concentration of OVA was 100 μg / mL, and each injected mouse was 0.2mL, and the mice in the blank control group were injected with an equal amount of PBS. On the 22nd to 27th day, the mice in the model group, the rosmarinic acid group, the embodiment 1-3 group and the comparative example 1-2 group were anesthetized with ether every day and the concentration of OVA was 2mg / mL, 50μL per mouse, and the mice in the normal control group were injected with an equal amount of PBS. On the 25th, 26th and 27th days, rosmarinic acid, Example 1-3 group and Comparative Example 1-2 group were intraperitoneally injected into mice every day, wherein rosmarinic acid, Example 1-3 group and Comparative Example 1-2 group were injected with 20 mg rosmarinic acid / kg body weight every day, and the administration was carried out 1 hour after the stimulation. The model group and the normal control group were intraperitoneally injected with an equal amount of normal saline into the mice, and samples were collected for subsequent experiments 24 hours after the last nasal drip operation.
[0035] Effect of rosmarinic acid on cell differentiation and count in bronchoalveolar lavage fluid (BALF)
[0036] 24 hours after the last nasal drip operation, the mice were killed by ether over-anesthesia, fixed, cut the neck skin of the mice, separated and fully exposed the trachea, made an "I"-shaped incision above the trachea, inserted a homemade cannula, injected 0.5mL of pre-cooled PBS with a syringe, rinsed and aspirated, repeated three times, collected BALF, centrifuged the alveolar lavage fluid at 4°C, 3000r / min for 10 minutes, and stored the supernatant in a refrigerator at 80°C for determination of cytokine content in BALF. The bottom cell pellet was resuspended in PBS, the cells were smeared, stained with Swiss Giemsa stain, and used for cell classification and counting. The results of cell classification and counting are shown in Table 1.
[0037] Table 1: White blood cell differential count in BALF (106 / mL)
[0038] Group Total number of cells Neutrophils Acid granulocytes Blank control group 1.38±0.42 0.39±0.12 0.018±0.002 Model Group 5.68±1.21 1.68±0.35 1.64±0.38 Rosmarinic acid group 2.89±0.89 0.89±0.13 0.58±0.12 Example 1 Group 1.52±0.72# 0.48±0.08# 0.24±0.11# Example 2 Group 1.69±0.63# 0.57±0.11# 0.31±0.13# Example 3 Group 1.76±0.88# 0.56±0.13# 0.34±0.08# Comparative Example 1 2.92±0.97 0.91±0.18 0.64±0.18 Comparative Example 2 3.15±1.02 0.98±0.23 0.89±0.24
[0039] Note: #P<0.01vs. rosmarinic acid group.
[0040] The above results show that OVA stimulation causes the total number of cells in BALF, the number of neutrophils and the number of eosinophils to increase significantly (p<0.01). However, rosmarinic acid, embodiment 1-3 group and comparative example 1-2 group can significantly reduce the total number of cells in BALF (p<0.05), the number of neutrophils (p<0.01) and the number of eosinophils (p<0.01). However, compared to the rosmarinic acid group, the embodiment 1-3 group of the present invention can further significantly reduce the total number of cells in BALF (p<0.05), the number of neutrophils (p<0.01) and the number of eosinophils (p<0.01). Especially embodiment 1 group, due to the ratio of rosmarinic acid and tanshinone IIA, it can further reduce the total number of cells in BALF, the number of neutrophils and the number of eosinophils, which is the most preferred embodiment of the present invention.
[0041] After collecting bronchoalveolar lavage fluid, the secretion levels of IL-4, IL-5 and IL-13 in the airway BALF of OVA-induced mouse allergic asthma were determined according to the instructions of the mouse IL-4, IL-5 and IL-13 ELISA detection kit.
[0042] Table 2: Concentrations of IL-4, IL-5 and IL-13 in bronchoalveolar lavage fluid (pg / mL)
[0043] Group IL-4 IL-5 IL-13 Blank control group 42.28±7.89 11.89±1.05 18.38±2.30 Model Group 105.34±8.32 35.37±4.32 59.36±1.89 Rosmarinic acid group 64.59±5.68 23.15±3.05 38.49±1.28 Example 1 Group 49.31±6.12# 16.57±2.01# 25.78±1.05# Example 2 Group 50.69±5.37# 17.89±1.89# 26.81±1.39# Example 3 Group 51.38±5.97# 18.16±1.95# 26.91±1.88# Comparative Example 1 65.35±6.02 24.38±2.56 39.48±2.37 Comparative Example 2 66.79±6.15 23.18±3.15 39.11±2.56
[0044] Note: #P<0.05vs. rosmarinic acid group.
[0045] The results showed that compared with the normal blank control group, the ovalbumin stimulation caused the IL-4, IL-5 and IL-13 contents in the BALF of the model group to be significantly increased (p<0.01). Compared with the model group, the Example 1-3 group and the Comparative Example 1-2 group were able to reduce the concentrations of Th2 cytokines IL-4 (p<0.01), IL-5 (p<0.05) and IL-13 (p<0.01) in the BALF. However, compared with the rosmarinic acid group, the Example 1-3 group of the present invention was able to further significantly reduce the concentrations of Th2 cytokines IL-4 (p<0.05), IL-5 (p<0.05) and IL-13 (p<0.05) in the BALF.
[0046] The above test results show that the use of the liposome drug of the present invention can significantly enhance the therapeutic effect of the drug on asthma, and is expected to play a greater therapeutic value in clinical practice.
[0047] The above describes the preferred embodiments of the present invention, but it is not intended to limit the present invention. Those skilled in the art may make improvements and changes to the embodiments disclosed herein without departing from the scope and spirit of the present invention.
Claims
1. A liposome drug, characterized in that: The liposome is a liposome formed by a phospholipid bilayer membrane, wherein rosmarinic acid is encapsulated inside the liposome, and tanshinone IIA is encapsulated in the phospholipid bilayer membrane of the liposome.
2. The liposome drug according to claim 1, characterized in that The liposomes are formed from DPPC, DSPG and cholesterol.
3. The liposome drug according to claim 2, characterized in that: The weight ratio of DPPC, DSPG and cholesterol is 40-60:5-8:12-15.
4. The liposome drug according to claim 1, characterized in that The weight ratio of rosmarinic acid to tanshinone IIA is 60:15-120.
5. The liposome drug according to claim 1, characterized in that: The weight ratio of rosmarinic acid to tanshinone IIA is 60:
18.
6. The liposome drug according to any one of claims 1 to 5, characterized in that: The liposome medicine does not contain other active ingredients.
7. The method for preparing the liposome drug according to any one of claims 1 to 6, characterized in that: It includes the following steps: (1) Preparation of rosmarinic acid solution: adding rosmarinic acid to purified water and dissolving by ultrasonication; (2) Mixing the rosmarinic acid solution with the lipid solution: Mix tanshinone IIA, DPPC, DSPG and cholesterol, then add chloroform and methanol to mix easily, and shake gently to dissolve tanshinone IIA, DPPC and DSPG; The solvent was removed using a rotary evaporator until a thin film of dry lipids was deposited on the wall of the container; the rosmarinic acid solution was added to the round-bottom flask containing the thin layer of dry lipids and sonicated at 60-70 degrees Celsius; (3) Extrusion: The preparation was extruded at 60-70 degrees Celsius using a heated stainless steel extruder equipped with a polycarbonate membrane. The extrusion process was repeated 9-11 times to obtain liposomes of 80-200 nm. After extrusion, NaOH was added to the liposome solution to adjust the pH to 6.5-7.0 to obtain liposomal drugs.
8. Use of the liposome drug according to any one of claims 1 to 6 in the preparation of a drug for relieving asthma.
Citation Information
Patent Citations
Application of rosmarinic acid to preparing medicines for treating asthma
CN105997974A
Medicine composition containing radix salviae miltiorrhizae active ingredients and recipe particle preparation method and application thereof
CN108524488A
Chitosan modified salvia miltiorrhiza extract double-phase medicine-carrying nano lipid carrier and preparation method thereof
CN109045109A
Composite hydrogel material loaded with rosmarinic acid and preparation method and application of composite hydrogel material
CN110742859A
